Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience

@article{DAlessandris2012TargetedTW,
  title={Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience},
  author={Quintino Giorgio D’Alessandris and Nicola Montano and Tonia Cenci and Maurizio Martini and Liverana Lauretti and Federico Bianchi and Luigi Maria Larocca and G Maira and Eduardo Fern{\'a}ndez and Roberto Pallini},
  journal={Acta Neurochirurgica},
  year={2012},
  volume={155},
  pages={33-40}
}
BackgroundAdvances in comprehension of molecular biology of glioblastoma (GBM) have led to the development of targeted therapies. The aim of the present study was to evaluate the efficacy and safety of a targeted therapeutic approach in which administration of bevacizumab and erlotinib was tailored on the molecular profile of recurrent GBM.MethodsWe prospectively enrolled ten adult patients suffering from recurrent GBM who had undergone surgical resection and standard chemo-radiotherapy. Tumor… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

Biomarkers for glioblastoma multiforme: status quo

VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 34 REFERENCES

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

  • The New England journal of medicine
  • 2005
VIEW 11 EXCERPTS
HIGHLY INFLUENTIAL

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Biology of angiogenesis and invasion in glioma

  • Neurotherapeutics
  • 2009
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL